Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07209111 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
A Phase 2 study of Neoplasm Malignant, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT07209111 is a Phase 2 study of Neoplasm Malignant that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 150 participants, below the 270-participant average among 7 other Neoplasm Malignant trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT07209111, a Phase 2 study of Neoplasm Malignant, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare * About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.
Conditions Studied
Interventions
- BIOLOGICAL Cetuximab
- DRUG Calderasib
Study Locations (20)
Shanghai Municipality
- Shanghai Chest Hospital ( Site 1300) - Shanghai
- Fudan University Shanghai Cancer Center ( Site 1325) - Shanghai
- Zhongshan Hospital,Fudan University ( Site 1301) - Shanghai
Zhejiang
- Zhejiang Cancer Hospital ( Site 1311) - Hangzhou
- Taizhou Hospital of Zhejiang Province ( Site 1312) - Linhai
Maryland
- Greater Baltimore Medical Center ( Site 1104) - Baltimore
Michigan
- START Midwest ( Site 1103) - Grand Rapids
New Jersey
- Rutgers Cancer Institute of New Jersey ( Site 1100) - New Brunswick
Utah
- START Mountain Region ( Site 1106) - West Valley City
Virginia
- Virginia Cancer Specialists ( Site 1102) - Fairfax
New South Wales
- Prince of Wales Hospital-Medical Oncology ( Site 1003) - Randwick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2032-04-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07209111
The ClinicalTrials.gov registry entry for NCT07209111 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 270-participant average among 7 other Neoplasm Malignant trials with a reported enrollment target (44% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasm Malignant appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT07209111 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Shanghai Municipality, Zhejiang, Maryland.
Frequently Asked Questions
What is clinical trial NCT07209111 about?
NCT07209111 is a clinical study titled "A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)". Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and ho...
What is the current status of trial NCT07209111?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-12-04. Estimated completion is 2032-04-09.
What conditions does trial NCT07209111 study?
This clinical trial studies the following conditions: Neoplasm Malignant.
What interventions are being tested in trial NCT07209111?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Calderasib (DRUG).
Who is sponsoring clinical trial NCT07209111?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07209111 being conducted?
This trial has 20 study locations across Maryland, Michigan, New Jersey, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm Malignant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
ACTIVE NOT RECRUITING · Phase 2
-
AIMS Cancer Outcomes Study
RECRUITING
-
EMPOWER 3: Improving Palliative Care Health Literacy and Utilization
ACTIVE NOT RECRUITING · NA
-
A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer
ACTIVE NOT RECRUITING · NA
-
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
ACTIVE NOT RECRUITING · Phase 1
-
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.